ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) had its price target boosted by analysts at HC Wainwright from $36.00 to $39.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 43.12% from the stock’s current price.
ArriVent BioPharma Price Performance
AVBP opened at $27.25 on Wednesday. The business’s 50-day moving average price is $26.99 and its two-hundred day moving average price is $25.97. ArriVent BioPharma has a 1 year low of $14.35 and a 1 year high of $36.37.
Hedge Funds Weigh In On ArriVent BioPharma
A number of large investors have recently bought and sold shares of AVBP. Rhumbline Advisers lifted its position in shares of ArriVent BioPharma by 30.1% in the second quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock worth $236,000 after purchasing an additional 2,942 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in ArriVent BioPharma during the 3rd quarter worth about $240,000. SG Americas Securities LLC bought a new stake in ArriVent BioPharma during the 3rd quarter worth about $280,000. JPMorgan Chase & Co. boosted its stake in shares of ArriVent BioPharma by 183.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company’s stock worth $292,000 after buying an additional 8,050 shares during the last quarter. Finally, MetLife Investment Management LLC grew its holdings in shares of ArriVent BioPharma by 168.9% in the 3rd quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock valued at $384,000 after acquiring an additional 10,269 shares in the last quarter. Institutional investors and hedge funds own 9.48% of the company’s stock.
ArriVent BioPharma Company Profile
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
See Also
- Five stocks we like better than ArriVent BioPharma
- The 3 Best Retail Stocks to Shop for in August
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Where Do I Find 52-Week Highs and Lows?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- The How And Why of Investing in Oil Stocks
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.